Further studies on the mechanism of antipsychotic action: potentiation by alpha-methyltyrosine of thioridazine effects in chronic schizophrenics.
D002908:Chronic Disease; D004357:Drug Synergism; D005069:Evaluation Studies as Topic; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008781:Methyltyrosines / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D012919:Social Behavior / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects; D013881:Thioridazine / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors
D008781:Methyltyrosines; D006897:Hydroxyindoleacetic Acid; D014446:Tyrosine 3-Monooxygenase; D013881:Thioridazine; D006719:Homovanillic Acid